Chelsee J. Jensen, PharmD, BCPS

Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.

With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.